U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C9H13NO2
Molecular Weight 167.205
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PHENYLEPHRINE

SMILES

CNC[C@H](O)C1=CC(O)=CC=C1

InChI

InChIKey=SONNWYBIRXJNDC-VIFPVBQESA-N
InChI=1S/C9H13NO2/c1-10-6-9(12)7-3-2-4-8(11)5-7/h2-5,9-12H,6H2,1H3/t9-/m0/s1

HIDE SMILES / InChI

Description
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204300lbl.pdf and https://www.drugs.com/pro/phenylephrine-and-chlorpheniramine-tablets.html

Phenylephrine is a powerful vasoconstrictor. It is used as a nasal decongestant and cardiotonic agent. Phenylephrine is a postsynaptic α1-receptor agonist with little effect on β-receptors of the heart. Parenteral administration of phenylephrine causes a rise in systolic and diastolic pressures, a slight decrease in cardiac output, and a considerable increase in peripheral resistance; most vascular beds are constricted, and renal, splanchnic, cutaneous, and limb blood flows are reduced while coronary blood flow is increased. Phenelephrine also causes pulmonary vessel constriction and subsequent increase in pulmonary arterial pressure. Vasoconstriction in the mucosa of the respiratory tract leads to decreased edema and increased drainage of sinus cavities. In general, α1-adrenergic receptors mediate contraction and hypertrophic growth of smooth muscle cells. α1-receptors are 7-transmembrane domain receptors coupled to G proteins, Gq/11. Three α1-receptor subtypes, which share approximately 75% homology in their transmembrane domains, have been identified: α1A (chromosome 8), α1B (chromosome 5), and α1D (chromosome 20). Phenylephrine appears to act similarly on all three receptor subtypes. All three receptor subtypes appear to be involved in maintaining vascular tone. The α1A-receptor maintains basal vascular tone while the α1B-receptor mediates the vasocontrictory effects of exogenous α1-agonists. Activation of the α1-receptor activates Gq-proteins, which results in intracellular stimulation of phospholipases C, A2, and D. This results in mobilization of Ca2+ from intracellular stores, activation of mitogen-activated kinase and PI3 kinase pathways and subsequent vasoconstriction. Phenylephrine produces its local and systemic actions by acting on α1-adrenergic receptors peripheral vascular smooth muscle. Stimulation of the α1-adrenergic receptors results in contraction arteriolar smooth muscle in the periphery. Phenylephrine decreases nasal congestion by acting on α1-adrenergic receptors in the arterioles of the nasal mucosa to produce constriction; this leads to decreased edema and increased drainage of the sinus cavities. Phenylephrine is mainly used to treat nasal congestion, but may also be useful in treating hypotension and shock, hypotension during spinal anaesthesia, prolongation of spinal anaesthesia, paroxysmal supraventricular tachycardia, symptomatic relief of external or internal hemorrhoids, and to increase blood pressure as an aid in the diagnosis of heart murmurs.

CNS Activity

Curator's Comment: Phenylephrine does not cross the blood–brain barrier

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
55.0 nM [EC50]
5.9 nM [EC50]
154.88 nM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
VAZCULEP

Approved Use

VAZCULEP (phenylephrine hydrochloride) is indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia.

Launch Date

-5.05007997E11
Diagnostic
Phenylephrine Hydrochloride Ophthalmic Solution

Approved Use

Indicated to dilate the pupil

Launch Date

-9.7839363E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
2959 pg/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PHENYLEPHRINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
4492 pg/mL
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PHENYLEPHRINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1354 pg/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PHENYLEPHRINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
2346 pg × h/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PHENYLEPHRINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
3900 pg × h/mL
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PHENYLEPHRINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
955.8 pg × h/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PHENYLEPHRINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1.93 h
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PHENYLEPHRINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1.64 h
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PHENYLEPHRINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1.89 h
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PHENYLEPHRINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
10 mg 1 times / day multiple, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, 34 years
n = 1
Health Status: unhealthy
Age Group: 34 years
Sex: M
Population Size: 1
Sources:
Disc. AE: Ischemic colitis...
AEs leading to
discontinuation/dose reduction:
Ischemic colitis (acute)
Sources:
40 mg 6 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 6 times / day
Route: oral
Route: multiple
Dose: 40 mg, 6 times / day
Sources:
unhealthy, 37.5 years (range: 19.0 - 77.0 years)
n = 112
Health Status: unhealthy
Condition: Seasonal Allergic Rhinitis
Age Group: 37.5 years (range: 19.0 - 77.0 years)
Sex: M+F
Population Size: 112
Sources:
Disc. AE: Chest pain, Jaw pain...
Other AEs: Nervous system disorders, Headache...
AEs leading to
discontinuation/dose reduction:
Chest pain (1 patient)
Jaw pain (1 patient)
Other AEs:
Nervous system disorders (3.6%)
Headache (2.7%)
Gastrointestinal disorders (8%)
Dry mouth (2.7%)
Nausea (3.6%)
Sources:
10 % 3 times / day multiple, ophthalmic
Recommended
Dose: 10 %, 3 times / day
Route: ophthalmic
Route: multiple
Dose: 10 %, 3 times / day
Sources:
healthy, > 1 year
Health Status: healthy
Age Group: > 1 year
Sources:
Other AEs: Eye pain, Blurred vision...
Other AEs:
Eye pain
Blurred vision
Photophobia
Allergic conjunctivitis
Sources:
250 ug single, intravenous
Recommended
Dose: 250 ug
Route: intravenous
Route: single
Dose: 250 ug
Sources:
unhealthy, adult
AEs

AEs

AESignificanceDosePopulation
Ischemic colitis acute
Disc. AE
10 mg 1 times / day multiple, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
unhealthy, 34 years
n = 1
Health Status: unhealthy
Age Group: 34 years
Sex: M
Population Size: 1
Sources:
Chest pain 1 patient
Disc. AE
40 mg 6 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 6 times / day
Route: oral
Route: multiple
Dose: 40 mg, 6 times / day
Sources:
unhealthy, 37.5 years (range: 19.0 - 77.0 years)
n = 112
Health Status: unhealthy
Condition: Seasonal Allergic Rhinitis
Age Group: 37.5 years (range: 19.0 - 77.0 years)
Sex: M+F
Population Size: 112
Sources:
Jaw pain 1 patient
Disc. AE
40 mg 6 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 6 times / day
Route: oral
Route: multiple
Dose: 40 mg, 6 times / day
Sources:
unhealthy, 37.5 years (range: 19.0 - 77.0 years)
n = 112
Health Status: unhealthy
Condition: Seasonal Allergic Rhinitis
Age Group: 37.5 years (range: 19.0 - 77.0 years)
Sex: M+F
Population Size: 112
Sources:
Dry mouth 2.7%
40 mg 6 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 6 times / day
Route: oral
Route: multiple
Dose: 40 mg, 6 times / day
Sources:
unhealthy, 37.5 years (range: 19.0 - 77.0 years)
n = 112
Health Status: unhealthy
Condition: Seasonal Allergic Rhinitis
Age Group: 37.5 years (range: 19.0 - 77.0 years)
Sex: M+F
Population Size: 112
Sources:
Headache 2.7%
40 mg 6 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 6 times / day
Route: oral
Route: multiple
Dose: 40 mg, 6 times / day
Sources:
unhealthy, 37.5 years (range: 19.0 - 77.0 years)
n = 112
Health Status: unhealthy
Condition: Seasonal Allergic Rhinitis
Age Group: 37.5 years (range: 19.0 - 77.0 years)
Sex: M+F
Population Size: 112
Sources:
Nausea 3.6%
40 mg 6 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 6 times / day
Route: oral
Route: multiple
Dose: 40 mg, 6 times / day
Sources:
unhealthy, 37.5 years (range: 19.0 - 77.0 years)
n = 112
Health Status: unhealthy
Condition: Seasonal Allergic Rhinitis
Age Group: 37.5 years (range: 19.0 - 77.0 years)
Sex: M+F
Population Size: 112
Sources:
Nervous system disorders 3.6%
40 mg 6 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 6 times / day
Route: oral
Route: multiple
Dose: 40 mg, 6 times / day
Sources:
unhealthy, 37.5 years (range: 19.0 - 77.0 years)
n = 112
Health Status: unhealthy
Condition: Seasonal Allergic Rhinitis
Age Group: 37.5 years (range: 19.0 - 77.0 years)
Sex: M+F
Population Size: 112
Sources:
Gastrointestinal disorders 8%
40 mg 6 times / day multiple, oral
Highest studied dose
Dose: 40 mg, 6 times / day
Route: oral
Route: multiple
Dose: 40 mg, 6 times / day
Sources:
unhealthy, 37.5 years (range: 19.0 - 77.0 years)
n = 112
Health Status: unhealthy
Condition: Seasonal Allergic Rhinitis
Age Group: 37.5 years (range: 19.0 - 77.0 years)
Sex: M+F
Population Size: 112
Sources:
Allergic conjunctivitis
10 % 3 times / day multiple, ophthalmic
Recommended
Dose: 10 %, 3 times / day
Route: ophthalmic
Route: multiple
Dose: 10 %, 3 times / day
Sources:
healthy, > 1 year
Health Status: healthy
Age Group: > 1 year
Sources:
Blurred vision
10 % 3 times / day multiple, ophthalmic
Recommended
Dose: 10 %, 3 times / day
Route: ophthalmic
Route: multiple
Dose: 10 %, 3 times / day
Sources:
healthy, > 1 year
Health Status: healthy
Age Group: > 1 year
Sources:
Eye pain
10 % 3 times / day multiple, ophthalmic
Recommended
Dose: 10 %, 3 times / day
Route: ophthalmic
Route: multiple
Dose: 10 %, 3 times / day
Sources:
healthy, > 1 year
Health Status: healthy
Age Group: > 1 year
Sources:
Photophobia
10 % 3 times / day multiple, ophthalmic
Recommended
Dose: 10 %, 3 times / day
Route: ophthalmic
Route: multiple
Dose: 10 %, 3 times / day
Sources:
healthy, > 1 year
Health Status: healthy
Age Group: > 1 year
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes
PubMed

PubMed

TitleDatePubMed
Altered baroreflex control of heart rate in bradykinin B2-receptor knockout mice.
1999 Dec
Involvement of ATP-sensitive potassium channels in a model of a delayed vascular hyporeactivity induced by lipopolysaccharide in rats.
1999 Jul
Microphysiometric analysis of human alpha1a-adrenoceptor expressed in Chinese hamster ovary cells.
1999 Jun
Investigation of the effects of some alkaloidal alpha1-adrenoceptor antagonists on human hyperplastic prostate.
1999 Jun 25
Characterization of human recombinant alpha(2A)-adrenoceptors expressed in Chinese hamster lung cells using intracellular Ca(2+) changes: evidence for cross-talk between recombinant alpha(2A)- and native alpha(1)-adrenoceptors.
2000 Apr
Specific role of the extracellular signal-regulated kinase pathway in angiotensin II-induced cardiac hypertrophy in vitro.
2000 Apr 1
Alpha(1) adrenergic agonist induction of p21(waf1/cip1) mRNA stability in transfected HepG2 cells correlates with the increased binding of an AU-rich element binding factor.
2000 Apr 21
Gene transfer of endothelial nitric oxide isoform decreases rat hindlimb vascular resistance in vivo.
2000 Aug 10
Neuropeptide Y (NPY) potentiates phenylephrine-induced mitogen-activated protein kinase activation in primary cardiomyocytes via NPY Y5 receptors.
2000 Feb 15
Calcineurin-mediated hypertrophy protects cardiomyocytes from apoptosis in vitro and in vivo: An apoptosis-independent model of dilated heart failure.
2000 Feb 18
Inhibitory regulation of hypertrophy by endogenous atrial natriuretic peptide in cultured cardiac myocytes.
2000 Jan
Bupivacaine inhibits baroreflex control of heart rate in conscious rats.
2000 Jan
Minidose bupivacaine-fentanyl spinal anesthesia for surgical repair of hip fracture in the aged.
2000 Jan
Viral-mediated gene delivery of constitutively activated G alpha s alters vasoreactivity.
2000 Jan-Feb
Fine structure and plasticity of barosensitive neurons in the nucleus of solitary tract.
2000 Jul 3
Presence of NMDA receptor subunits in the male lower urogenital tract.
2000 Jul-Aug
The Rho effector, PKN, regulates ANF gene transcription in cardiomyocytes through a serum response element.
2000 Jun
Altered molecular response to adrenoreceptor-induced cardiac hypertrophy in Egr-1-deficient mice.
2000 Mar
Phosphorylation of GATA-4 is involved in alpha 1-adrenergic agonist-responsive transcription of the endothelin-1 gene in cardiac myocytes.
2000 May 5
The effect of phenylephrine on pain and flare intensity in eyes with uveitis.
2000 Oct
Intracarotid infusion of the nitric oxide synthase inhibitor, L-NMMA, modestly decreases cerebral blood flow in human subjects.
2000 Sep
Heparin-mediated hypotension associated with cardiac surgery.
2000 Sep
Effects of salt intake and angiotensin II on vascular reactivity to endothelin-1.
2001 Feb
Smooth muscle-targeted overexpression of insulin-like growth factor I results in enhanced vascular contractility.
2001 Feb
Nitric oxide-mediated arteriolar dilation after endothelial deformation.
2001 Feb
Vascular NAD(P)H oxidase is distinct from the phagocytic enzyme and modulates vascular reactivity control.
2001 Feb
Interaction of rapid nongenomic cardiovascular aldosterone effects with the adrenergic system.
2001 Feb
Heat, but not mechanical hyperalgesia, following adrenergic injections in normal human skin.
2001 Feb 1
Flow (shear stress)-induced endothelium-dependent dilation is altered in mice lacking the gene encoding for dystrophin.
2001 Feb 13
The transient receptor potential protein homologue TRP6 is the essential component of vascular alpha(1)-adrenoceptor-activated Ca(2+)-permeable cation channel.
2001 Feb 16
A N-terminal PTHrP peptide fragment void of a PTH/PTHrP-receptor binding domain activates cardiac ET(A) receptors.
2001 Jan
Exercise attenuates alpha-adrenergic-receptor responsiveness in skeletal muscle vasculature.
2001 Jan
Catecholamine responses to alpha-adrenergic blockade during exercise in women acutely exposed to altitude.
2001 Jan
Should the angiotensin II antagonists be discontinued before surgery?
2001 Jan
[Ca(2+)](i) signaling in renal arterial smooth muscle cells of pregnant rat is enhanced during inhibition of NOS.
2001 Jan
Endothelin and nitric oxide mediate reduced myogenic reactivity of small renal arteries from pregnant rats.
2001 Jan
Increased alpha(1)- and alpha(2)-adrenoceptor-mediated contractile responses of human skeletal muscle resistance arteries in chronic limb ischemia.
2001 Jan
Gender-related distinctions in protein kinase C activity in rat vascular smooth muscle.
2001 Jan
Assessment of baroreflex sensitivity in patients with preserved and impaired left ventricular function by means of the Valsalva manoeuvre and the phenylephrine test.
2001 Jan
Receptor reserve analysis of the human alpha(2C)-adrenoceptor using.
2001 Jan 12
Relaxation of rat aorta by adenosine in diabetes with and without hypertension: role of endothelium.
2001 Jan 19
Pharmacological profile of T-1032, a novel specific phosphodiesterase type 5 inhibitor, in isolated rat aorta and rabbit corpus cavernosum.
2001 Jan 5
Insulin-induced relaxation of rat mesenteric artery is mediated by Ca(2+)-activated K(+) channels.
2001 Jan 5
Phosphatidylinositol 4,5-bisphosphate is acting as a signal molecule in alpha(1)-adrenergic pathway via the modulation of acetylcholine-activated K(+) channels in mouse atrial myocytes.
2001 Jan 5
In vivo regulation of Na/Ca exchanger expression by adrenergic effectors.
2001 Mar
Endothelial cell protein kinase G inhibits release of EDHF through a PKG-sensitive cation channel.
2001 Mar
Reciprocal regulation of cGMP-mediated vasorelaxation by soluble and particulate guanylate cyclases.
2001 Mar
Endogenous estrogen mediates vascular reactivity and distensibility in pregnant rat mesenteric arteries.
2001 Mar
Topical phenylephrine increases anal canal resting pressure in patients with faecal incontinence.
2001 Mar
EDHF contributes to strain-related differences in pulmonary arterial relaxation in rats.
2001 Mar
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment: Also used as Ophthalmic Solution or oral tablets http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203510s000lbl.pdf https://www.drugs.com/dosage/chlorpheniramine-phenylephrine.html
VAZCULEP (phenylephrine hydrochloride) Injection, 10 mg/mL, is injected intravenously either as a bolus or in a dilute solution as a continuous infusion. Dilute before administration. Dosing for treatment of hypotension during anesthesia Bolus intravenous injection: 40 mcg to 100 mcg every 1-2 minutes as needed, not to exceed 200 mcg. Intravenous infusion: 10 mcg/min to 35 mcg/min, titrating to effect, not to exceed 200 mcg/min.
Route of Administration: Intravenous
The hypertrophic phenotype of neonatal rat cardiomyocyte cultures (cardiomyocyte size, sarcomeric organization, total protein synthesis, c-fos expression) mediated by phenylephrine (10 uM) was counteracted by the selective A1 receptor agonist
Name Type Language
PHENYLEPHRINE
EP   HSDB   INN   MART.   MI   VANDF   WHO-DD  
INN  
Official Name English
J8.601K
Code English
M-SYMPATHOL
Common Name English
M-SYNEPHRINE
Common Name English
AB-101 (PHENYLEPHRINE)
Code English
(R)-PHENYLEPHRINE
Common Name English
(-)-3 HYDROXY-.ALPHA.-((METHYLAMINO)METHYL)BENZENEMETHANOL
Systematic Name English
PHENYLEPHRINE, (R)-
Common Name English
PHENYLEPHRINE MINIMS
Brand Name English
R(-)-MEZATON
Common Name English
PHENYLEPHRINE [HSDB]
Common Name English
(-)-1-(3-HYDROXYPHENYL)-2-METHYLAMINOETHANOL
Systematic Name English
M-OXEDRINE
Common Name English
Phenylephrine [WHO-DD]
Common Name English
PHENYLEPHRINE [VANDF]
Common Name English
PHENYLEPHRINE [MI]
Common Name English
META-SYNEPHRINE
Common Name English
phenylephrine [INN]
Common Name English
M-SYMPATOL
Common Name English
PHENYLEPHRINE [EP IMPURITY]
Common Name English
PHENYLEPHRINE [EP MONOGRAPH]
Common Name English
METASYNEPHRINE
Common Name English
(-)-PHENYLEPHRINE
Common Name English
PHENYLEPHRINE [MART.]
Common Name English
Classification Tree Code System Code
LIVERTOX 773
Created by admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
WHO-VATC QR01BA03
Created by admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
WHO-VATC QS01FB01
Created by admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
WHO-VATC QR01AA04
Created by admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
WHO-VATC QC01CA06
Created by admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
WHO-ATC R01BA03
Created by admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
WHO-ATC R01AB01
Created by admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
WHO-ATC R01BA53
Created by admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
WHO-VATC QS01GA55
Created by admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
WHO-ATC C01CA06
Created by admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
WHO-ATC S01BB01
Created by admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
WHO-VATC QS01GA05
Created by admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
WHO-VATC QR01AB01
Created by admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
WHO-ATC S01FB51
Created by admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
WHO-ATC S01FB01
Created by admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
FDA ORPHAN DRUG 147201
Created by admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
WHO-VATC QR01BA53
Created by admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
NCI_THESAURUS C29709
Created by admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
WHO-ATC S01GA55
Created by admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
NDF-RT N0000186105
Created by admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
WHO-ATC R01AA04
Created by admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
WHO-ATC S01GA05
Created by admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
FDA ORPHAN DRUG 359011
Created by admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
Code System Code Type Description
NCI_THESAURUS
C62067
Created by admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
PRIMARY
CAS
59-42-7
Created by admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
PRIMARY
RXCUI
8163
Created by admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
PRIMARY
MESH
D010656
Created by admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
PRIMARY
ChEMBL
CHEMBL1215
Created by admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
PRIMARY
RXCUI
325517
Created by admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
ALTERNATIVE
DAILYMED
1WS297W6MV
Created by admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
PRIMARY
CHEBI
8093
Created by admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
PRIMARY
EPA CompTox
DTXSID9023465
Created by admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
PRIMARY
IUPHAR
485
Created by admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
PRIMARY
EVMPD
SUB09788MIG
Created by admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
PRIMARY
HSDB
3383
Created by admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
PRIMARY
DRUG BANK
DB00388
Created by admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
PRIMARY
LACTMED
Phenylephrine
Created by admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
PRIMARY
PUBCHEM
6041
Created by admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
PRIMARY
ECHA (EC/EINECS)
200-424-8
Created by admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
PRIMARY
DRUG CENTRAL
2146
Created by admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
PRIMARY
NDF-RT
N0000009917
Created by admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
PRIMARY Adrenergic alpha1-Agonists [MoA]
FDA UNII
1WS297W6MV
Created by admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
PRIMARY
MERCK INDEX
m8668
Created by admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
PRIMARY Merck Index
SMS_ID
100000088260
Created by admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
PRIMARY
WIKIPEDIA
PHENYLEPHRINE
Created by admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
PRIMARY
INN
4174
Created by admin on Fri Dec 15 15:06:37 UTC 2023 , Edited by admin on Fri Dec 15 15:06:37 UTC 2023
PRIMARY